

AMENDMENTS TO THE CLAIMS

Please replace all prior listing of claims with the following listing:

1. to 25. Canceled.

26. (Currently Amended) A monoclonal antibody which specifically binds to a AB11-x polypeptide at one or more epitopes present on the first 5 to 7 N-terminal amino acids, wherein said antibody does not specifically bind to a full length AB1-40/42 peptide, and The monoclonal antibody of claim 17, which is wherein the monoclonal antibody is produced by the hybridoma cell with the accession number LMBP 5896CB.

27. (Currently Amended) A monoclonal antibody which specifically binds to a AB11-x polypeptide at one or more epitopes present on the first 5 to 7 N-terminal amino acids, wherein said antibody does not specifically bind to a full length AB1-40/42 peptide, and The monoclonal antibody of claim 17, which is wherein the monoclonal antibody is produced by the hybridoma cell with the accession number LMBP 5897CB.

28. Canceled.

29. (Currently Amended) A hybridoma which produces a monoclonal antibody which specifically binds to a AB11-x polypeptide at one or more epitopes present on the first 5 to 7 N-terminal amino acids, wherein said antibody does not specifically bind to a full length AB1-40/42 peptide, wherein the hybridoma The hybridoma of claim 28 which has the accession number LMBP 5896CB.

30. (Currently Amended) A hybridoma which produces a monoclonal antibody which specifically binds to a AB11-x polypeptide at one or more epitopes present on the first 5 to 7 N-terminal amino acids, wherein said antibody does not specifically bind to a full length AB1-40/42 peptide, wherein the hybridoma The hybridoma of claim 28 which has the accession number LMBP 5897CB.

31. to 36. Canceled.